Brain metastases are the most common intracranial tumours in adults, occurring in 20 to 40 percent of all cancer patients. They are not a single clinical entity. The right treatment depends on the number and size of metastases, the primary cancer type and its systemic control status, the patient's performance score, and the specific technologies available at the treating centre. For international patients who must travel to access adequate care, choosing incorrectly is not just a logistical error — it can mean receiving WBRT when SRS was appropriate, or being treated without the immunotherapy integration that the primary cancer requires.
This guide maps the current brain metastases treatment landscape, explains what each approach involves, and outlines the criteria that differentiate hospitals capable of delivering the full range of modern treatment from those that are not.
Understanding the Treatment Options: What Has Changed in 2025
The brain metastases treatment landscape has shifted considerably in the past five years. Stereotactic radiosurgery has displaced whole-brain radiotherapy as the primary modality for most patients, and systemic therapy combinations have become more integrated into intracranial disease management. Knowing which option applies to your situation is the starting point for evaluating any hospital.
Stereotactic Radiosurgery (SRS)
SRS remains the mainstay of brain metastases treatment, particularly effective for patients with a relatively small number of metastases, typically one to four, and for lesions that do not cause significant mass effect. The ASCO-SNO-ASTRO guideline supports SRS for up to four metastases, with expanding evidence for larger numbers when total treatment volume is manageable. SRS delivers high-dose radiation with millimetre precision in one to five sessions, without any incision or hospital admission in most cases.
Recent advances have expanded SRS indications to patients with multiple metastases and lesions close to eloquent anatomical regions, where precise targeting allows treatment while preserving neurocognitive function. Improvements in systemic therapy have also increased life expectancy for metastatic cancer patients, enabling multiple courses of SRS across different disease timepoints.
Platforms delivering SRS include the Gamma Knife (dedicated intracranial system), CyberKnife (robotic radiosurgery), and LINAC-based systems using VMAT or IMRT with radiosurgical framing. The choice between platforms depends on lesion size, location, and number rather than one being categorically superior.
Whole-Brain Radiotherapy (WBRT)
WBRT delivers radiation across the entire brain and was previously the standard for patients with multiple metastases or poor prognosis. It remains relevant for patients with numerous or very small disseminated lesions not amenable to individual SRS targeting, patients with leptomeningeal disease, and as salvage therapy following SRS failure. WBRT carries a documented risk of neurocognitive decline, and the 2025 ScienceDirect radiotherapy update confirms that quality-of-life outcomes for patients receiving first-line SRS followed by WBRT at recurrence are better than those receiving combined treatment immediately. The preference where technically feasible is therefore SRS first.
Hippocampal-avoiding WBRT with concurrent memantine reduces neurocognitive toxicity versus standard WBRT and should be available at any centre recommending whole-brain irradiation.
Surgical Resection
Surgery is indicated when a brain metastasis is large (typically above three centimetres), causing significant mass effect or obstructive hydrocephalus, is accessible without high neurological risk, and the patient has good performance status. Surgery provides immediate decompression and tissue for histological confirmation. MD Anderson-led prospective data confirmed that SRS of the surgical cavity after complete resection of one to three metastases significantly lowers local recurrence compared to post-operative observation. Surgery therefore works most powerfully in combination with post-operative SRS rather than as a standalone approach.
Systemic Therapy: Targeted Agents and Immunotherapy
The integration of systemic therapy with intracranial-directed treatment has become one of the most significant developments in brain metastases management. For primary cancers with actionable mutations, targeted therapies can achieve meaningful intracranial response rates. EGFR-mutant non-small cell lung cancer responds to osimertinib with high intracranial efficacy. HER2-positive breast cancer responds to tucatinib plus capecitabine plus trastuzumab. BRAF V600E-mutant melanoma responds to BRAF/MEK inhibition. Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) have intracranial activity in melanoma and lung cancer.
The 2025 ScienceDirect radiotherapy update notes specific drug-radiotherapy sequencing considerations: anti-BRAF agents should be withheld at least three days before and after fractionated SRS, and trastuzumab emtansine carries an increased neurological toxicity risk when combined with stereotactic radiation. These nuances require a neuro-oncology team with specific experience in drug-radiation interaction management, which is not universally available.
The Five Criteria That Differentiate Brain Metastases Treatment Hospitals
Choosing the right hospital for brain metastases treatment in India requires applying specific criteria rather than relying on general rankings.
Criterion 1: SRS Platform and Treatment Volume
The most critical infrastructure question is whether the hospital has a dedicated SRS system and what annual treatment volume it performs. SRS requires either a dedicated intracranial apparatus (Gamma Knife or CyberKnife) or a modern LINAC with radiosurgical capability and real-time image guidance. Centres with dedicated platforms and high treatment volumes produce more consistent targeting accuracy and better dosimetric outcomes.
Ask specifically: which SRS platform is used, how many brain metastases cases are treated per year on this platform, and what is the centre's planning system for SRS (dose-volume histogram review, conformality index)?
Criterion 2: Multidisciplinary Neuro-Oncology Tumour Board
Brain metastases treatment decisions should never rest with a single specialist. A neuro-oncology tumour board integrating neurosurgery, radiation oncology, medical oncology, neuroradiology, and neuropathology reviews every case before treatment begins. This is the setting in which SRS versus surgery versus WBRT decisions are made, drug-radiation sequencing is planned, and primary cancer molecular profiling is integrated with intracranial disease management. A hospital that treats brain metastases without a functioning tumour board is making these decisions in isolation.
Criterion 3: Neurosurgical Capability for Complex Cases
Not every brain metastasis requires surgery. But when surgery is indicated for large, symptomatic lesions, the quality of the neurosurgical team directly determines the functional outcome. Confirm whether the centre offers neuronavigation-guided resection, intraoperative neurophysiological monitoring for lesions near eloquent cortex, and post-operative SRS of the surgical cavity. These capabilities together represent the surgical arm of evidence-based brain metastases management.
For context on what advanced neurosurgical capability involves at a centre like SIMS Hospital, Chennai, read: How Dr. K. R. Suresh Bapu Approaches Complex Brain Tumor Treatment Cases
Criterion 4: Molecular Profiling and Targeted Therapy Access
The primary cancer's molecular profile is now inseparable from brain metastases treatment planning. A hospital without on-site or affiliated molecular pathology capable of testing for EGFR, ALK, ROS1, BRAF, HER2, PD-L1, and KRAS cannot optimally integrate systemic therapy with intracranial treatment. Next-generation sequencing panels for solid tumours should be available, with results turnaround within one to two weeks.
Criterion 5: Imaging Infrastructure and Treatment Response Assessment
Brain metastases management requires high-resolution MRI with gadolinium contrast at diagnosis, at six weeks after SRS, and at three-month intervals thereafter. Advanced sequences including perfusion MRI, MR spectroscopy, and PET imaging for distinguishing radiation necrosis from tumour progression are increasingly important as SRS use expands and treatment response assessment becomes more complex.
Confirm whether the centre has a 3T MRI with dedicated brain metastases protocol sequences and an experienced neuroradiologist interpreting brain tumour imaging rather than a general radiologist.
What International Patients Should Prepare Before Arriving in India
Arriving well-prepared reduces evaluation time and allows the treating team to move toward a treatment plan faster.
Documents to Send in Advance
-
Complete primary cancer history: pathology report with molecular markers, all prior treatment records, most recent staging scans
-
Brain MRI with gadolinium contrast (must be recent, ideally within four weeks of arrival)
-
Performance status and current medications
-
Any prior brain treatment records (previous SRS, WBRT, or surgery)
Send these to Karetrip for case review by the neuro-oncology team before the medical visa application. This allows confirmation that the proposed centre has the specific treatment the patient needs (SRS platform, tumour board, targeted therapy access) and provides a realistic treatment plan and timeline before travel is booked.
Realistic Timeline for International Patients
| Treatment pathway | Evaluation time | Treatment duration | In-India stay |
|---|---|---|---|
| SRS alone (1 to 5 sessions) | 3 to 5 days | 1 to 5 days | 10 to 14 days |
| Surgery + post-op SRS | 3 to 5 days | Surgery + 2 to 4 weeks recovery | 3 to 5 weeks |
| WBRT (10 to 15 fractions) | 2 to 3 days | 2 to 3 weeks | 3 to 4 weeks |
| Surgery alone | 3 to 5 days | Surgery + 10 to 14 days recovery | 2 to 3 weeks |
Cost of Brain Metastases Treatment in India
Navigating advanced neuro-oncological care requires balancing immediate access to high-precision technology with realistic financial planning. India has become a premier global destination for complex brain tumor care, offering international patients elite clinical interventions at a deeply competitive price point.
Advanced Treatment Modalities and Price Breakdown
The table below details the cost structure of advanced surgical, radiosurgical, and molecular diagnostic options in India compared to standard pricing frameworks in the United States and the United Kingdom:
| Treatment | India cost | USA / UK equivalent |
|---|---|---|
| SRS (Gamma Knife / CyberKnife, 1 session) | Rs. 1,50,000 to Rs. 2,50,000 (USD 1,800 to USD 3,000) | USD 10,000 to USD 30,000 |
| SRS (multi-session, 3 to 5 fractions) | Rs. 2,00,000 to Rs. 4,00,000 (USD 2,400 to USD 4,800) | USD 15,000 to USD 40,000 |
| Craniotomy for brain metastasis | Rs. 2,50,000 to Rs. 5,00,000 (USD 3,000 to USD 6,000) | USD 30,000 to USD 80,000 |
| WBRT (full course) | Rs. 80,000 to Rs. 1,50,000 (USD 960 to USD 1,800) | USD 8,000 to USD 20,000 |
| Molecular profiling (NGS panel) | Rs. 30,000 to Rs. 60,000 (USD 360 to USD 720) | USD 3,000 to USD 5,000 |
All figures represent 60 to 85 percent savings versus the USA or UK, using the same internationally sourced SRS platforms and molecularly targeted agents.
How Karetrip Connects International Patients to the Right Brain Metastases Centre
Two patients with brain metastases can have completely different treatment requirements depending on their primary cancer, lesion number and size, molecular profile, and prior treatment history. Karetrip reviews each patient's imaging and oncology records before recommending a centre, confirming that the proposed hospital has the specific SRS platform, tumour board structure, and targeted therapy access the patient's case requires. From pre-travel case review and medical visa coordination, through accommodation near the treating hospital, discharge documentation, and post-treatment follow-up coordination, Karetrip manages every element of the international patient journey for brain metastases treatment in India.
Chat with our Medical care assistant, RUA, for quick guidance and support and take the first step toward getting your case reviewed by a neuro-oncology team equipped for your specific situation.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Brain metastases require urgent evaluation by qualified oncologists and neurosurgeons. Always consult your treating team before making any treatment decisions.